1	Effects of successful percutaneous coronary intervention of chronic total occlusions with
2	demonstrable viability or ischemia: A protocol for a systematic review
3	
4	Luís Leite ^{1,2,3,4} *¶, Tomás Carlos ¹ ¶, Gustavo Campos ¹ , Helena Donato ⁵ , Rodolfo Silva ^{2,3,4} , Antero
5	Abrunhosa ^{2,4} , Lino Gonçalves ^{1,3,6} , Maria João Ferreira ^{1,2,3,4}
6	
7	1 Cardiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
8	2 Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra,
9	Portugal
10	3 Faculty of Medicine, University of Coimbra, Coimbra, Portugal
11	4 Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Coimbra,
12	Portugal
13	5 Documentation and Scientific Information Service, Centro Hospitalar e Universitário de
14	Coimbra, Coimbra, Portugal
15	6 Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal
16	
17	* Corresponding author
18	E-mail: <u>luispcleite@gmail.com</u>
19	ORCID: 0000-0002-8493-6935
20	
21	[¶] These authors contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 ABSTRACT

24 Background

Chronic coronary total occlusion (CTO) is a common finding in patients referred to coronary 25 26 angiography. To sustain blood flow distally to the occlusion site, collateral circulation is formed 27 from preexisting vessels. While these collaterals may partial or completely preserve perfusion at 28 rest, they may be insufficient when increased blood flow is needed. According to current 29 guidelines, percutaneous coronary intervention (PCI) is recommended solely in patients with 30 resistant angina despite optimal medical therapy or when a large area of documented ischemia in 31 the territory of the occluded vessel is present. Randomised controlled trials (RCTs) suggest its 32 benefit in the improvement of patients' quality of life and symptoms, despite their conflicting 33 results concerning prognosis and left ventricular function. However, most of these studies often 34 lack data regarding myocardial ischemic burden and viability, assessed by imaging methods. 35 Therefore, the purpose of the systematic review is to comprise and analyse the literature on whether viability or ischemia-guided PCI of CTO, identified by imaging methods, has an impact 36 37 on the clinical outcomes of the patients.

38

39 Methods

40 We will conduct a thorough research in different databases, including PubMed/MEDLINE, 41 EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core 42 Collection, Clinical trials in the European Union, and ClinicalTrials.gov. We will include RCTs, 43 cohort studies, cross-sectional studies, and case-control studies, in which patients with established CTO were tested for viability and/or ischemia before the decision to perform PCI and were 44 45 evaluated by post-intervention testing or clinical endpoint follow-up. Two authors will 46 independently review the selected studies, and any discrepancies will be solved by a third element. 47 Subsequently, data from the various eligible studies will be extracted and analysed by two 48 different authors. No subgroup analysis is planned.

49 Ethics and disclosure: Ethical approval will not be required for this study as it is an analysis of 50 previously published articles (i.e., secondary data). The results will be published in a peer-51 reviewed journal.

52 **PROSPERO registration:** CRD42023426858.

53

54 INTRODUCTION

55 Chronic total coronary occlusions (CTO) are defined as angiographic evidence of complete vessel 56 occlusion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 within an epicardial 57 coronary artery, and an estimated duration of at least three months [1]. Its prevalence is not 58 entirely established, with reporting rates varying from 16%-18% [2] to approximately 30% [3,4] 59 in patients referred for coronary angiography. Notably, within the subgroup diagnosed with stable 60 angina pectoris, it is believed that up to one fourth of this population exhibit this type of coronary 61 disease [5].

In the presence of a CTO, blood supply to the myocardium is solely from collateral vessels. The development of a collateral circulation network is a complex physiologic response induced by the chronic state of hypoxia, by the pressure gradient created, as well as by several different humoral factors. There is an individual variation on the ability to develop well-formed collaterals that may avoid a transmural myocardial infarction and preserve ventricular function. However, it is widely believed that, although the collateral network may have the ability to preserve perfusion at rest, it could be insufficient when increased blood flow is needed [4].

Moreover, the chronic supply defect from the main artery may cause myocardium hibernation, characterized by reversible reduced regional contractile function that could partial or completely recover after reperfusion or revascularization [6,7]. Bearing this in mind, it would be reasonable to refer these patients to percutaneous coronary intervention (PCI). Nonetheless, current guidelines, prevailing since 2018, recommend CTO PCI only in patients with angina resistant to

optimal medical therapy or with a large area of documented ischemia in the territory of the
occluded vessel (with a class of evidence IIa) [8].

76 Until recently, there was reluctance in attempting PCI in CTO patients, with solely an estimate 10%-15% of all eligible CTO lesions being referred [9,10]. This was based on lower procedural 77 78 success and high rate of complications, such as urgent coronary artery bypass graft (CABG) 79 surgery, coronary perforation, acute reocclusion, collateral loss and major adverse cardiac events, 80 including death [11]. During the past decade, important developments in interventional materials 81 and techniques have led to the achievement of high rates of procedural success, defined as a residual stenosis <30% with antegrade TIMI flow grade 3 in the CTO target vessel [12,13]. 82 Indeed, recent studies such as the EXPLORE trial, suggested that PCI of CTO was safe even in 83 patients with a concurrent ST-elevation myocardial infarction (STEMI) in other main artery, with 84 85 no periprocedural death or emergency CABG [14]. Also, evidence suggests that the higher 86 mortality and morbidity found in patients with multivessel disease, in comparison to single-vessel 87 disease, might be partially attributed to the presence of concomitant CTO, contributing to the declining of LV function [15]. 88

Hence, it urges to clearly define which patients are candidates for PCI on top of optimal medical 89 90 therapy (OMT), since currently we have no accurate method that predicts who will benefit from that [16]. In the past few years, randomized clinical trials (RCTs) have focused on evaluating 91 92 whether CTO-PCI in addition to OMT improved patients' symptoms and prognosis. Overall, it is 93 generally accepted that it improves patients' quality of life and symptoms, mainly angina and 94 physical exercise limitation, when compared to no PCI [16-20]. DECISION-CTO trial was one 95 of the few studies that did not show this relative benefit [21]. However, in this study, 96 revascularization of non-CTO lesions was performed after randomization in OMT+CTO-PCI or 97 solely OMT, potentially contributing to the absence of differences [20]. When prognosis and LV 98 function are concerned, studies show more conflicting results. In a subgroup analysis of the 99 EXPLORE trial, Elias et al. demonstrated that in the dysfunctional segments afflicted by the 100 chronic occlusion, PCI was associated with marked improvement of regional function, measured

by cardiac magnetic resonance imaging (cMRI), especially if transmural extent of infarction (TEI) 101 102 was lower than 50% [22]. Different research using cMRI suggested that in segments with TEI 103 below 75% there was a tendency for improvement in segmental wall thickening (SWT), and that 104 the extent of improvement in LV ejection fraction (LVEF) correlated with the size of infarcted 105 area before procedure [23]. However, mean LVEF remained practically unchanged, with the same 106 finding being observed in the COMET-CTO trial [20]. Furthermore, REVASC trial showed no 107 differences in regional wall motion of the myocardium affected by the CTO lesions after PCI 108 [24]. Moreover, IMPACTOR-CTO trial evaluated the impact of PCI on the composite endpoint 109 of all-cause death, myocardial infarction, and unplanned revascularization six months after the 110 procedure, with no significant differences described [17]. Lastly, OAT-trial demonstrated a 111 tendency for reinfarction in the PCI group, at a follow-up time of approximately four years [25].

In the published RCTs there are very few data regarding myocardial ischemic burden and viability, often assessed by imaging methods, such as cMRI, single-photon emission computed tomography (SPECT), stress echocardiography or positron emission tomography (PET). Currently, ISCHEMIA-CTO trial is underway to evaluate whether CTO-PCI improves quality of life and major adverse cardiovascular events in patients with significant ischemic burden [26].

To the best of our knowledge, a systematic review of the literature on whether viability or ischemia-guided PCI of CTO have an impact in clinical outcomes is yet to be conducted. We aim to address this subject, evaluating all-cause mortality, nonfatal myocardial infarction, symptomatic improvement, and ischemic burden reduction in the follow-up of patients with documented viability or ischemia previously to the decision to perform PCI.

122

123 METHODS AND ANALYSIS

The protocol and completed systematic review will be reported following the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA) Protocols and the Prisma checklists,
respectively.

127

128 Eligibility criteria

129 In this systematic review, our objective is to identify RCTs, cohort studies (prospective or 130 retrospective in nature), cross-sectional studies, and case-control studies, in which patients with 131 established CTO were tested for viability and/or ischemia before the decision to perform PCI and were evaluated by post-intervention testing or clinical endpoint follow-up. The diverse testing 132 133 modalities encompassed cMRI, PET, SPECT or stress echocardiography. Studies lacking 134 viability and/or ischemia testing before PCI or lacking measured clinical endpoints or postintervention testing will be excluded. Table 1 presents our PICO description. If the same study is 135 136 represented in different articles, the one with the largest sample size or more suitable data for our specific aim will be selected. No restriction regarding publication year will be set; therefore, we 137 138 will be including studies from inception to the 31st of October 2023. There will be no restrictions on publication status or language of publication. We will resort to a professional translator if 139 140 needed.

141

142 **Table 1.** PICO description

Abbreviation	PICO	Elements
Р	Population	Patients with a CTO who had performed viability or ischemia exams before the decision to perform PCI, with a post- intervention clinical evaluation and/or cardiac testing (LV function, ischemia burden evaluation)
Ι	Intervention	Successful PCI with documented viability or ischemia
С	Comparator	Patients with a CTO who had no demonstrable viability or ischemia before performing successful PCI, had

		demonstrable viability or ischemia but have not performed
		PCI or in whom PCI was unsuccessful
		All-cause mortality, nonfatal myocardial infarction,
0	Outcome	symptomatic improvement, left ventricular function
		improvement, and ischemic burden reduction

143

144 Information sources

145 We will comprise literature published in the following databases: PubMed/MEDLINE, 146 EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core 147 Collection, and we will also consult Clinical trials in the European Union, and ClinicalTrials.gov 148 to check for ongoing or unpublished trials. If any relevant unpublished trial is found, the corresponding author listed will be contacted to grant access to the required information. If no 149 150 response is given or the author decides not to share the data, this will be listed as the reason for 151 excluding such a trial Grev literature will also be queried to include all possible articles on the subject. We will also hand search in the reference list of the included articles. No pre-prints will 152 153 be included.

154

155 Search strategy

Detailed search strategies will be conducted in the previously described databases, in consultation with a medical librarian with expertise in systematic review searching. The search strategy will contain controlled vocabulary (e.g., Medical Subject Headings (MeSH)) and text words searches adapted to each one of the databases regarding its own special requirements. To merge the search terms effectively, Boolean operators "AND" and "OR" will be used. An example of the search strategy used in PubMed/MEDLINE is depicted in Table 2.

163 **Table 2.** Search strategy

	/MEDLINE
Query	Search
	(Coronary Occlusion[Title/Abstract]) AND (chronic[Title/Abstract]))) OR (((
	"Coronary Occlusion/diagnosis"[Mesh] OR "Coronary Occlusion/diagnostic
#1	imaging"[Mesh] OR "Coronary Occlusion/therapy"[Mesh])) AND "Chronic
	Disease"[Mesh])
	("Heart/diagnostic imaging"[Mesh] OR "Cardiac Imaging Techniques"[Mesh] OR
	"Ventricular Function, Left"[Mesh] OR "Positron-Emission Tomography"[Mesh]
	OR "Magnetic Resonance Imaging, Cine" [Mesh] OR "Adenosine" [Mesh] OR
	"Contrast Media"[Mesh] OR "Dobutamine"[Mesh] OR "Gadolinium"[Mesh] OR
	"Echocardiography"[Mesh] OR "Fibrosis"[Mesh] OR "Necrosis"[Mesh] OR
	"Myocardial Ischemia"[Mesh] OR "Myocardial Stunning"[Mesh] OR "Ventricular
	Dysfunction, Left"[Mesh]) OR (Cardiac Imaging Techniques[Title/Abstract] OR
	Techniques, Intracardiac Imaging[Title/Abstract] OR Ventricular Function,
#2	Left[Title/Abstract] OR Myocardial Perfusion Imaging[Title/Abstract] OR
#2	Positron-Emission Tomography[Title/Abstract] OR Positron Emission
	Tomography Computed Tomography[Title/Abstract] OR Magnetic Resonance
	Imaging Cine[Title/Abstract] OR Adenosine[Title/Abstract] OR Contrast
	Media[Title/Abstract] OR Dobutamine[Title/Abstract] OR
	Gadolinium[Title/Abstract] OR Echocardiography[Title/Abstract] OR
	Echocardiography, Stress[Title/Abstract] OR Fibrosis[Title/Abstract] OR
	Necrosis[Title/Abstract] OR Myocardial Ischemia[Title/Abstract] OR Ventricular
	Dysfunction, Left[Title/Abstract] OR Myocardial Stunning[Title/Abstract] OR
	Myocardial hibernation[Title/Abstract])

	(Percutaneous Coronary Intervention[Title/Abstract] OR Angioplasty, Balloon,
	Coronary[Title/Abstract] OR Atherectomy, Coronary[Title/Abstract] OR Coronary
#3	Revascularization, Percutaneous[Title/Abstract] OR Myocardial
	Revascularization[Title/Abstract] OR "percutaneous coronary intervention"[MeSH
	Terms] OR "Myocardial Revascularization"[Mesh])
#4	Search #1 AND #2 AND #3

164

165 Data management

All studies and literature reviewed will be imported to EndNote citation software and allduplicates will be removed.

168

169 Selection process

Two independent reviewers will conduct the selection phase of the studies during the month of January 2024. Any discrepancy found between the two reviewers will be solved by a third reviewer. The remaining studies will be full-text reviewed and included or excluded according to our predefined eligibility criteria. A flow chart similar to Fig. 1 will be presented to detail the study selection process for this review.

175

176 Fig. 1. Flowchart diagram presenting the selection process for the studies.

177

178 Data collection process

Data collection will be performed after the selection process. Two independent reviewers will
extract the relevant data for our systematic review from the various eligible studies. A third
reviewer will solve any found discrepancies and validate the other results.

182

183 Data items

184 Collected data from the obtained studies will encompass authors' names, sample size, study 185 design, number of eligible patients, average age, gender distribution, type of cardiac exam conducted pre and post intervention, decision to perform PCI or solely OMT, success of PCI, 186 definition of myocardial ischemia and viability assessment for each study and type of clinical 187 188 follow-up performed. Reasons for the exclusion of full text records will be reported.

189 Details on the selection process of the studies and included patients will be documented into a 190 flow chart, following PRISMA checklists.

191

192 Outcomes

Our systematic review aims to assess whether viability or ischemia-guided PCI of CTO have an 193 impact on clinical outcomes. To achieve this, we will analyse diverse parameters across the 194 195 different studies such as all-cause mortality, nonfatal myocardial infarction, symptomatic 196 improvement, left ventricular improvement and ischemic burden reduction post PCI (successful 197 vs non successful) or solely OMT. No subgroup analysis is planned at first hand; however, it may 198 be performed if motivated by the literature review.

199

200 **Risk of bias**

201 Risk of bias of individual studies will be assessed independently by two reviewers, with a third 202 reviewer assisting with any disagreements. Since we will be including diverse types of studies, 203

we will use different tools to identify the risk of bias depending on each study's characteristics.

204 We will use Cochrane Risk of Bias 2.0 -tool for assessing risk of bias in randomized trials, and

205 ROBINS-I tool - Risk Of Bias In Non-randomized Studies - of Interventions.

206

207 Data synthesis

- 208 We will provide a narrative synthesis of the findings from the selected studies, structured around
- 209 the viability and/or ischemia exam, and type of clinical outcome measured.

210

211 Confidence in cumulative evidence

- 212 The strength of the body evidence will be assessed using the Grading Recommendations
- 213 Assessment, Development and Evaluation (GRADE).

214

215 Patient and public involvement

This is a protocol for a systematic review based on previously published data. No participantrecruitment or involvement will be necessary.

218

219 Ethics and dissemination

220 This systematic review will be conducted upon public and already published data; therefore, no

ethical approval is necessary. The resulting work will be published in a peer-reviewed journal and

- presented at relevant conferences. Any necessary modifications of the protocol will be dated and
- reported through a detailed description of the rationale for the adjustments.

224

225 DISCUSSION

Even though CTO are a common finding in patients with coronary artery disease, there are conflicting results regarding the benefit of performing PCI in these lesions. Most clinical studies

228 lack data regarding myocardial ischemia burden and viability documentation, therefore a 229 systematic review on the clinical impact of ischemia/viability-guided CTO PCI is needed. 230 This study has limitations as it is a secondary study dependent on the published data. Moreover, 231 there are several imaging modalities to diagnose ischemia or viability, each one with its own 232 criteria. On the other hand, the clinical impact of the intervention is measured with different 233 outcomes within each study, which could make the discussion more demanding to perform. Therefore, we will provide a narrative synthesis of the findings, structured around the diagnostic 234 235 exams and type of clinical outcome.

236

237 SUPPORTING INFORMATION

238 S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and Meta- Analysis

239 Protocols) 2015 checklist: Recommended items to address in a systematic review protocol*.

240


241 AUTHOR CONTRIBUTIONS

- 242 Conceptualization: Luís Leite, Tomás Carlos, Maria João Ferreira.
- 243 Investigation: Luís Leite, Tomás Carlos, Gustavo Campos, Lino Gonçalves, Maria João Ferreira.
- 244 Methodology: Luís Leite, Tomás Carlos, Gustavo Campos, Helena Donato.
- 245 Supervision: Maria João Ferreira.
- 246 Writing original draft: Luís Leite, Tomás Carlos, Gustavo Campos.
- 247 Writing review & editing: Luís Leite, Tomás Carlos, Gustavo Campos, Helena Donato, Rodolfo
- 248 Silva, Antero Abrunhosa, Lino Gonçalves, Maria João Ferreira.

250	Data	Availability Statement: No datasets were generated or analyzed during the current study. All	
251	relev	ant data from this study will be made available upon study completion.	
252			
253	Fund	ing: The authors received no specific funding for this work.	
254			
255	Competing interests: The authors have declared that no competing interests exist.		
256			
257	REF	ERENCES	
258 259 260	1.	Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, et al. Recanalisation of Chronic Total coronary Occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012;8:139–45.	
261 262 263	2.	Azzalini L, Jolicoeur EM, Pighi M, Millán X, Picard F, Tadros VX, et al. Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion. Am J Cardiol. 2016;118:1128–35.	
264 265 266	3.	Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.	
267 268 269 270	4.	Stuijfzand WJ, Driessen RS, Raijmakers PG, Rijnierse MT, Maeremans J, Hollander MR, et al. Prevalence of ischaemia in patients with a chronic total occlusion and preserved left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging. 2017;18:1025–33.	
271 272 273	5.	Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current perspectives on coronary chronic total occlusions. J Am Coll Cardiol. 2012;59:991–7.	
274 275	6.	Heusch G. Myocardial stunning and hibernation revisited. Nat Rev Cardiol. 2021;18:522–36.	
276 277 278	7.	Ferrari R, Ceconi C, Curello S, Benigno M, Canna G La, Visioli O. Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. J Cardiovasc Pharmacol. 1996;28:18–26.	
279 280 281	8.	Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.	
282 283	9.	Grantham JA, Marso SP, Spertus J, House J, Holmes DR, Rutherford BD. Chronic Total Occlusion Angioplasty in the United States. JACC Cardiovasc Interv. 2009;2:479–86.	

284 285 286	10.	Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current Perspectives on Coronary Chronic Total Occlusions. J Am Coll Cardiol. 2012;59:991–7.
287 288 289 290	11.	Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi L V, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001;38:409–14.
291 292 293 294	12.	Christopoulos G, Karmpaliotis D, Alaswad K, Lombardi WL, Grantham JA, Rangan B V., et al. The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: Insights from a US multicenter registry. Catheter Cardiovasc Interv. 2014;84:646–51.
295 296 297	13.	Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, et al. Recanalisation of Chronic Total coronary Occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012;8:139–45.
298 299 300	14.	Henriques JPS, Hoebers LP, Råmunddal T, Laanmets P, Eriksen E, Bax M, et al. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI. J Am Coll Cardiol. 2016;68:1622–32.
301 302 303 304	15.	Claessen BE, van der Schaaf RJ, Verouden NJ, Stegenga NK, Engstrom AE, Sjauw KD, et al. Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2009;2:1128–34.
305 306	16.	Rinfret S, Sandesara PB. Reducing ischemia with CTO PCI. JACC Cardiovasc Interv. 2021;14:1419–22.
307 308	17.	Obedinskiy AA, Kretov EI, Boukhris M, Kurbatov VP, Osiev AG, Ibn Elhadj Z, et al. The IMPACTOR-CTO Trial. JACC Cardiovasc Interv. 2018;11:1309–11.
309 310 311	18.	Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39:2484–93.
312 313 314	19.	Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the Early Health Status Benefits of Successful Chronic Total Occlusion Recanalization. Circ Cardiovasc Qual Outcomes. 2010;3:284–90.
315 316 317	20.	Juricic SA, Tesic MB, Galassi AR, Petrovic ON, Dobric MR, Orlic DN, et al. Randomized Controlled Comparison of Optimal Medical Therapy with Percutaneous Recanalization of Chronic Total Occlusion (COMET-CTO). Int Heart J. 2021;62:16–22.
318 319 320	21.	Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. Circulation. 2019;139:1674–83.
321 322 323 324	22.	Elias J, van Dongen IM, Hoebers LP, Ouweneel DM, Claessen BEPM, Råmunddal T, et al. Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. J Cardiovasc Magn Reson. 2017 Dec 19;19:53.

325 326 327	23.	Baks T, van Geuns RJ, Duncker DJ, Cademartiri F, Mollet NR, Krestin GP, et al. Prediction of Left Ventricular Function After Drug-Eluting Stent Implantation for Chronic Total Coronary Occlusions. J Am Coll Cardiol. 2006;47:721–5.
328 329 330	24.	Mashayekhi K, Nührenberg TG, Toma A, Gick M, Ferenc M, Hochholzer W, et al. A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion. JACC Cardiovasc Interv. 2018;11:1982–91.
331 332 333	25.	Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–407.
334 335 336 337	26.	Råmunddal T, Holck EN, Karim S, Eftekhari A, Escaned J, Ioanes D, et al. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design. Am Heart J. 2023;257:41–50.



intervention (n=x)

Studies included in qualitative analysis (n=x)

Figure 1

Inclusion